Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15180524 | 0.95 | TP53 (0.48) | MAPTKDM4ETHRBEPHX2GPR119 | |
| SCHEMBL15167906 | 0.89 | MAPT (0.49) | MAPTKDM4ETHRBGPR119TP53 | |
| SCHEMBL30366127 | 0.89 | MEN1 (0.49) | MAPTKDM4ETHRBGPR119TP53 | |
| SCHEMBL30899639 | 0.89 | MEN1 (0.49) | MAPTKDM4ETHRBGPR119TP53 | |
| SCHEMBL13941156 | 0.88 | THRB (0.50) | MAPTKDM4ETHRBGPR119TP53 | |
| SCHEMBL30456267 | 0.86 | GPR119 (0.52) | MAPTKDM4ETHRBGPR119 | |
| SCHEMBL25723292 | 0.86 | GPR119 (0.52) | MAPTKDM4ETHRBGPR119 | |
| SCHEMBL31701805 | 0.85 | GPR119 (0.49) | MAPTKDM4ETHRBGPR119TP53 | |
| SCHEMBL15167435 | 0.85 | TP53 (0.46) | MAPTKDM4ETHRBGPR119TP53 | |
| SCHEMBL21085244 | 0.82 | KDM4E (0.52) | MAPTKDM4ETHRBEPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | MAPT 4505/4885KDM4E 725/4885THRB 4280/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | MAPT 4265/4885KDM4E 723/4885THRB 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.